Structured evidence table for Saffron Stress Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Saffron Stress Randomized Trial | In recent years, a growing body of scientific evidence supporting several of these traditional uses has shown the potential of saffron and its main ingredients—crocins, crocetin, safranal, and picrocrocin—as pharmacologically relevant compounds. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Stress Randomized Trial | By integrating evidence from in vitro studies, animal models, and clinical trials, this review critically assesses saffron’s potential as a multi-target pharmacological agent and identifies key limitations and future directions for its development within pharmaceutical and integrative medicine frameworks. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Stress Randomized Trial | Considering the scope of disease areas covered, this review is intended to be a broad narrative overview rather than an exhaustive systematic evaluation of each disease, with a focus on critically evaluating study quality, level of evidence, gaps between preclinical findings and clinical applicability, and limitations across sections. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Stress Randomized Trial | Crocus sativus 1 2 3 4 5 6 Natural products remain one of the main sources of pharmacologically bioactive compounds (BACs) and have played a fundamental role in the development of new drugs. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Stress Randomized Trial | The present narrative review reports the main preclinical and clinical results obtained by using supplementation of saffron or its pure components in neurodegeneration, with special emphasis on age-related macular degeneration. | 4 | Maggi MA (2026) | Saffron as a Retinal Neuroprotectant: A Narrative Review of Preclinical Studies and Clinical Results. |
| Saffron Stress Randomized Trial | Beyond that, this article will address shared pathways between neurodegenerative diseases of the eye and the brain. | 4 | Maggi MA (2026) | Saffron as a Retinal Neuroprotectant: A Narrative Review of Preclinical Studies and Clinical Results. |
Source documents